Migration history and risk of psychosis: results from the multinational EU-GEI study.

First-episode psychosis first-generation migrants migration adversities migration history psychosis risk social disadvantages

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 11 2 2021
medline: 5 1 2023
entrez: 10 2 2021
Statut: ppublish

Résumé

Psychosis rates are higher among some migrant groups. We hypothesized that psychosis in migrants is associated with cumulative social disadvantage during different phases of migration. We used data from the EUropean Network of National Schizophrenia Networks studying Gene-Environment Interactions (EU-GEI) case-control study. We defined a set of three indicators of social disadvantage for each phase: pre-migration, migration and post-migration. We examined whether social disadvantage in the pre- and post-migration phases, migration adversities, and mismatch between achievements and expectations differed between first-generation migrants with first-episode psychosis and healthy first-generation migrants, and tested whether this accounted for differences in odds of psychosis in multivariable logistic regression models. In total, 249 cases and 219 controls were assessed. Pre-migration (OR 1.61, 95% CI 1.06-2.44, The cumulative effect of social disadvantages before, during and after migration was associated with increased odds of psychosis in migrants, independently of ethnicity or length of stay in the country of arrival. Public health initiatives that address the social disadvantages that many migrants face during the whole migration process and post-migration psychological support may reduce the excess of psychosis in migrants.

Sections du résumé

BACKGROUND
Psychosis rates are higher among some migrant groups. We hypothesized that psychosis in migrants is associated with cumulative social disadvantage during different phases of migration.
METHODS
We used data from the EUropean Network of National Schizophrenia Networks studying Gene-Environment Interactions (EU-GEI) case-control study. We defined a set of three indicators of social disadvantage for each phase: pre-migration, migration and post-migration. We examined whether social disadvantage in the pre- and post-migration phases, migration adversities, and mismatch between achievements and expectations differed between first-generation migrants with first-episode psychosis and healthy first-generation migrants, and tested whether this accounted for differences in odds of psychosis in multivariable logistic regression models.
RESULTS
In total, 249 cases and 219 controls were assessed. Pre-migration (OR 1.61, 95% CI 1.06-2.44,
CONCLUSIONS
The cumulative effect of social disadvantages before, during and after migration was associated with increased odds of psychosis in migrants, independently of ethnicity or length of stay in the country of arrival. Public health initiatives that address the social disadvantages that many migrants face during the whole migration process and post-migration psychological support may reduce the excess of psychosis in migrants.

Identifiants

pubmed: 33563347
doi: 10.1017/S003329172000495X
pii: S003329172000495X
pmc: PMC9693676
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2972-2984

Auteurs

Ilaria Tarricone (I)

Department of Medical and Surgical Sciences, Bologna Transcultural Psychosomatic Team (BoTPT), University of Bologna, Bologna, Italy.
Department of Mental Health and Pathological Addiction, Local Health Authority, Bologna, Italy.

Giuseppe D'Andrea (G)

Department of Medical and Surgical Sciences, Bologna Transcultural Psychosomatic Team (BoTPT), University of Bologna, Bologna, Italy.
Department of Biomedical and NeuroMotor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

Hannah E Jongsma (HE)

PsyLife Group, Division of Psychiatry, UCL, London, England.
Department of Psychiatry, University of Cambridge, Cambridge, England.

Sarah Tosato (S)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy.

Charlotte Gayer-Anderson (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.

Simona A Stilo (SA)

Department of Mental Health and Addiction Services, ASP Crotone, Crotone, Italy.
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.

Federico Suprani (F)

Department of Medical and Surgical Sciences, Bologna Transcultural Psychosomatic Team (BoTPT), University of Bologna, Bologna, Italy.

Conrad Iyegbe (C)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.

Els van der Ven (E)

Mailman School of Public Health, Columbia University, New York, NY, USA.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

Diego Quattrone (D)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.

Marta di Forti (M)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.

Eva Velthorst (E)

Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA.

Paulo Rossi Menezes (P)

University Hospital, Section of Epidemiology, University of São Paulo, São Paulo, Brazil.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM, Centro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain.

Mara Parellada (M)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM, Centro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain.

Antonio Lasalvia (A)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy.

Caterina La Cascia (C)

Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Via G. La Loggia 1, 90129, Palermo, Italy.

Laura Ferraro (L)

Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Via G. La Loggia 1, 90129, Palermo, Italy.

Julio Bobes (J)

Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental, Oviedo, Spain.

Miguel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Department of Medicine, Neuroscience Institute, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Salud Mental, Barcelona, Spain.

Iulio Sanjuán (I)

Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental, Valencia, Spain.

Jose Luis Santos (JL)

Department of Psychiatry, Servicio de Psiquiatría Hospital 'Virgen de la Luz', Cuenca, Spain.

Manuel Arrojo (M)

Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Spain.

Cristina Marta Del-Ben (CM)

Neuroscience and Behavior Department, Ribeirão Preto Medical School, University of São Paulo, Brazil.

Giada Tripoli (G)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.
Department of Biomedicine, neurosciences, and advanced diagnostics, University of Palermo, Italy.

Pierre-Michel Llorca (PM)

Université Clermont Auvergne, EA 7280 Npsydo, Clermont-Ferrand, France.

Lieuwe de Haan (L)

Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.

Jean-Paul Selten (JP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

Andrea Tortelli (A)

Etablissement Public de Santé Maison Blanche, Paris, France.

Andrei Szöke (A)

Univ Paris Est Creteil (UPEC), AP-HP, Hôpitaux Universitaires « H. Mondor », DMU IMPACT, INSERM, IMRB, Fondation FondaMental, F-94010 Creteil, France.

Roberto Muratori (R)

Department of Mental Health and Pathological Addiction, Local Health Authority, Bologna, Italy.

Bart P Rutten (BP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jim van Os (J)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Psychiatry, Brain Center Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge, England.
CAMEO Early Intervention Service, Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, England.

James B Kirkbride (JB)

PsyLife Group, Division of Psychiatry, UCL, London, England.

Domenico Berardi (D)

Department of Biomedical and NeuroMotor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.

Craig Morgan (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH